Immix Biopharma, Inc. (IMMX)
9.31
+0.02
(+0.22%)
USD |
NASDAQ |
Oct 09, 11:12
Immix Biopharma Enterprise Value : 433.46M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 433.46M |
| October 07, 2026 | 447.77M |
| October 06, 2026 | 458.50M |
| October 05, 2026 | 493.55M |
| October 02, 2026 | 461.36M |
| October 01, 2026 | 500.70M |
| September 30, 2026 | 513.22M |
| September 29, 2026 | 522.88M |
| September 28, 2026 | 589.41M |
| September 25, 2026 | 553.64M |
| September 24, 2026 | 605.86M |
| September 23, 2026 | 621.60M |
| September 22, 2026 | 686.70M |
| September 21, 2026 | 660.94M |
| September 18, 2026 | 663.09M |
| September 17, 2026 | 678.83M |
| September 16, 2026 | 621.60M |
| September 15, 2026 | 637.34M |
| September 14, 2026 | 642.35M |
| September 11, 2026 | 637.34M |
| September 10, 2026 | 677.40M |
| September 09, 2026 | 649.50M |
| September 08, 2026 | 716.74M |
| September 04, 2026 | 763.96M |
| September 03, 2026 | 758.23M |
| Date | Value |
|---|---|
| September 02, 2026 | 767.53M |
| September 01, 2026 | 771.11M |
| August 31, 2026 | 772.54M |
| August 28, 2026 | 766.10M |
| August 27, 2026 | 792.57M |
| August 26, 2026 | 775.40M |
| August 25, 2026 | 804.02M |
| August 24, 2026 | 742.50M |
| August 21, 2026 | 746.07M |
| August 20, 2026 | 710.30M |
| August 19, 2026 | 712.45M |
| August 18, 2026 | 613.73M |
| August 17, 2026 | 580.11M |
| August 14, 2026 | 553.64M |
| August 13, 2026 | 550.06M |
| August 12, 2026 | 582.26M |
| August 11, 2026 | 590.84M |
| August 10, 2026 | 493.55M |
| August 07, 2026 | 464.22M |
| August 06, 2026 | 488.54M |
| August 05, 2026 | 451.35M |
| August 04, 2026 | 436.32M |
| August 03, 2026 | 371.23M |
| July 31, 2026 | 364.07M |
| July 30, 2026 | 380.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Atossa Therapeutics, Inc. | -2.054M |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 1.982B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.56M |
| Total Expenses (Quarterly) | 11.56M |
| EPS Diluted (Quarterly) | -0.1812 |
| Earnings Yield | -9.45% |
| Normalized Earnings Yield | -9.454 |